Toshihiko Ohtomo

2.0k total citations
31 papers, 1.5k citations indexed

About

Toshihiko Ohtomo is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Toshihiko Ohtomo has authored 31 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 14 papers in Radiology, Nuclear Medicine and Imaging and 10 papers in Oncology. Recurrent topics in Toshihiko Ohtomo's work include Monoclonal and Polyclonal Antibodies Research (13 papers), Glycosylation and Glycoproteins Research (12 papers) and Hepatocellular Carcinoma Treatment and Prognosis (10 papers). Toshihiko Ohtomo is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (13 papers), Glycosylation and Glycoproteins Research (12 papers) and Hepatocellular Carcinoma Treatment and Prognosis (10 papers). Toshihiko Ohtomo collaborates with scholars based in Japan, United States and Switzerland. Toshihiko Ohtomo's co-authors include Masayuki Tsuchiya, Koichiro Ono, Jun Ninomiya‐Tsuji, Kunihiro Matsumoto, Masahiko Mihara, Masashi Shiina, Taisuke Kajino, Masahiko Matsumoto, Shigeto Kawai and Norihisa Ohishi and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Toshihiko Ohtomo

31 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Toshihiko Ohtomo Japan 18 721 419 339 319 234 31 1.5k
Marie‐Françoise Bourgeade France 23 722 1.0× 474 1.1× 209 0.6× 379 1.2× 103 0.4× 46 1.5k
Gerhard Leder Germany 17 510 0.7× 194 0.5× 304 0.9× 469 1.5× 107 0.5× 32 1.4k
Changhua Ji United States 24 883 1.2× 281 0.7× 128 0.4× 495 1.6× 133 0.6× 57 1.7k
Zhen Zhao United States 17 1.5k 2.1× 365 0.9× 382 1.1× 745 2.3× 80 0.3× 34 2.4k
Raleigh D. Kladney United States 23 996 1.4× 281 0.7× 434 1.3× 505 1.6× 219 0.9× 33 1.8k
Daniel Branstetter United States 21 1.0k 1.5× 387 0.9× 386 1.1× 808 2.5× 88 0.4× 40 2.0k
Lydia Santell United States 21 617 0.9× 144 0.3× 486 1.4× 123 0.4× 175 0.7× 31 1.4k
Masaki Ri Japan 24 1000 1.4× 446 1.1× 119 0.4× 576 1.8× 89 0.4× 117 1.9k
Makiko Kawaguchi Japan 22 559 0.8× 318 0.8× 195 0.6× 312 1.0× 234 1.0× 72 1.3k

Countries citing papers authored by Toshihiko Ohtomo

Since Specialization
Citations

This map shows the geographic impact of Toshihiko Ohtomo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toshihiko Ohtomo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toshihiko Ohtomo more than expected).

Fields of papers citing papers by Toshihiko Ohtomo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toshihiko Ohtomo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toshihiko Ohtomo. The network helps show where Toshihiko Ohtomo may publish in the future.

Co-authorship network of co-authors of Toshihiko Ohtomo

This figure shows the co-authorship network connecting the top 25 collaborators of Toshihiko Ohtomo. A scholar is included among the top collaborators of Toshihiko Ohtomo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toshihiko Ohtomo. Toshihiko Ohtomo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pradier, Melanie F., Bernhard Reis, Lori Jukofsky, et al.. (2019). Case-control Indian buffet process identifies biomarkers of response to Codrituzumab. BMC Cancer. 19(1). 278–278. 3 indexed citations
2.
Yorita, Kenji, et al.. (2019). Intratumoral reciprocal expression of monocarboxylate transporter 4 and glypican-3 in hepatocellular carcinomas. BMC Research Notes. 12(1). 741–741. 6 indexed citations
3.
Chen, Gong, Ya‐Chi Chen, Bernhard Reis, et al.. (2018). Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab. Oncotarget. 9(12). 10436–10444. 13 indexed citations
4.
Carrasquillo, Jorge A., Joseph A. O’Donoghue, Volkan Beylergil, et al.. (2018). I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. EJNMMI Research. 8(1). 20–20. 31 indexed citations
5.
6.
Kaseb, Ahmed O., Manal M. Hassan, Şahin Laçin, et al.. (2016). Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget. 7(43). 69916–69926. 41 indexed citations
7.
Morris, Karen, Jonathan Tugwood, Leila Khoja, et al.. (2014). Circulating biomarkers in hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology. 74(2). 323–332. 61 indexed citations
8.
Abou‐Alfa, Ghassan K., Chia‐Jui Yen, Jorge A. Carrasquillo, et al.. (2014). Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170).. Journal of Clinical Oncology. 32(15_suppl). 4100–4100. 2 indexed citations
9.
Yen, Chia‐Jui, Bruno Daniele, Masatoshi Kudo, et al.. (2014). Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC; NCT01507168).. Journal of Clinical Oncology. 32(15_suppl). 4102–4102. 17 indexed citations
10.
Zhu, Andrew X., Philip J. Gold, Anthony B. El-Khoueiry, et al.. (2011). A phase I study of GC33, a recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 29(15_suppl). 4085–4085. 3 indexed citations
11.
Yorita, Kenji, Nobuyasu Takahashi, H. TAKAI, et al.. (2010). Prognostic significance of circumferential cell surface immunoreactivity of glypican‐3 in hepatocellular carcinoma. Liver International. 31(1). 120–131. 48 indexed citations
12.
Saitoh, Ryoichi, Toshihiko Ohtomo, Yukio Ito, et al.. (2005). Recovery of functional peptide transporter PepT1 in budded baculovirus fraction. Protein Expression and Purification. 46(1). 130–135. 11 indexed citations
13.
Shimamura, Takahiro, Hirotaka Ito, Junji Shibahara, et al.. (2005). Overexpression of MUC13 is associated with intestinal‐type gastric cancer. Cancer Science. 96(5). 265–273. 67 indexed citations
14.
Orita, Tetsuro, Hiroyuki Tsunoda, Kiyotaka Nakano, et al.. (2004). A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood. 105(2). 562–566. 54 indexed citations
15.
Ninomiya‐Tsuji, Jun, Taisuke Kajino, Koichiro Ono, et al.. (2003). A Resorcylic Acid Lactone, 5Z-7-Oxozeaenol, Prevents Inflammation by Inhibiting the Catalytic Activity of TAK1 MAPK Kinase Kinase. Journal of Biological Chemistry. 278(20). 18485–18490. 355 indexed citations
16.
Ono, Koichiro, Toshihiko Ohtomo, Jun Ninomiya‐Tsuji, & Masayuki Tsuchiya. (2003). A dominant negative TAK1 inhibits cellular fibrotic responses induced by TGF-β. Biochemical and Biophysical Research Communications. 307(2). 332–337. 61 indexed citations
17.
Ono, Koichiro, Toshihiko Ohtomo, Shigeo Sato, et al.. (2001). An Evolutionarily Conserved Motif in the TAB1 C-terminal Region Is Necessary for Interaction with and Activation of TAK1 MAPKKK. Journal of Biological Chemistry. 276(26). 24396–24400. 58 indexed citations
18.
Ohtomo, Toshihiko, Yasuhiro Sugamata, Koichiro Ono, et al.. (1999). Molecular Cloning and Characterization of a Surface Antigen Preferentially Overexpressed on Multiple Myeloma Cells. Biochemical and Biophysical Research Communications. 258(3). 583–591. 174 indexed citations
19.
Ono, Koichiro, Toshihiko Ohtomo, Kenji Yoshida, et al.. (1999). The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity. Molecular Immunology. 36(6). 387–395. 33 indexed citations
20.
Ohtomo, Toshihiko, Hideyuki Saito, Nobuo Inotsume, Masato Yasuhara, & Ken‐ichi Inui. (1996). Transport of levofloxacin in a kidney epithelial cell line, LLC-PK1: interaction with organic cation transporters in apical and basolateral membranes.. Journal of Pharmacology and Experimental Therapeutics. 276(3). 1143–1148. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marie‐Françoise Bourgeade Breakdown of academic impact, for papers by Gerhard Leder Breakdown of academic impact, for papers by Changhua Ji Breakdown of academic impact, for papers by Zhen Zhao Breakdown of academic impact, for papers by Raleigh D. Kladney Breakdown of academic impact, for papers by Daniel Branstetter Breakdown of academic impact, for papers by Lydia Santell Breakdown of academic impact, for papers by Masaki Ri Breakdown of academic impact, for papers by Makiko Kawaguchi
Rankless by CCL
2026